Monitor the June 24 KOL event for additional context and potential partnership or funding announcements. The Phase 1 study initiation is contingent on funding, so any news on capital raise or collaboration would be a key catalyst. The data, while early, could support a rapid development pathway if validated.
Price Chart
Executive Summary
Elicio Therapeutics reported preliminary clinical observations from the Phase 2 AMPLIFY-7P study showing three patients with metastatic mKRAS pancreatic cancer achieved confirmed complete radiographic and metabolic responses after progressing on ELI-002 7P and receiving subsequent nivolumab-based therapy. The company plans to initiate a Phase 1 study evaluating ELI-002 7P in combination with checkpoint inhibition in first-line metastatic PDAC, subject to funding. These data are early but notable given the historically low complete response rates (0-8%) in this indication.
Key Facts
- Three patients achieved 100% confirmed complete radiographic and complete metabolic responses after ELI-002 7P treatment and subsequent nivolumab-based therapy
- Two of three patients maintained complete responses for at least eight months, with one ongoing at >13 months
- All three patients were microsatellite stable (MSS) / mismatch repair proficient (MMR-p), a population historically resistant to checkpoint inhibitors
- Elicio intends to initiate a Phase 1 study in first-line metastatic mKRAS PDAC, subject to funding
- Company hosting a virtual KOL event on June 24, 2026 to discuss observations
Financial Impact
No financial figures provided in the filing; Phase 1 study is subject to funding
Risk Factors
- Phase 1 study is subject to funding – no guarantee of initiation
- Data based on only three patients; requires prospective validation
- Preliminary observations may not replicate in larger controlled studies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001601485-26-000048 |
| Document: a2026-06x17xxeltxxxmulti.htm | 0001601485-26-000048 |
| Document: 0001601485-26-000048-index-headers.html | 0001601485-26-000048 |
| Document: 0001601485-26-000048-index.html | 0001601485-26-000048 |
| Document: 0001601485-26-000048.txt | 0001601485-26-000048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.70 (−9.57%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.70 (−9.09%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.70 (−54.67%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.70 (−63.91%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.70 (−83.89%) |
Mar 17, 2026 32w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.70 (−86.04%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.70 (−86.07%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.70 (+86.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers